Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer-Reference-Cited by-同舟云学术

Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer

Published:2021-02-27 Issue:4 Volume:112 Page:1644-1654
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Harada Hiroki¹^ORCID,Soeno Takafumi¹,Nishizawa Nobuyuki²,Washio Marie¹,Sakuraya Mikiko¹,Ushiku Hideki¹,Niihara Masahiro¹^ORCID,Hosoda Kei¹^ORCID,Kumamoto Yusuke²,Naitoh Takeshi³,Sangai Takafumi⁴,Hiki Naoki¹^ORCID,Yamashita Keishi¹⁵^ORCID

Affiliation:

1. Department of Upper‐gastrointestinal Surgery Kitasato University School of Medicine Kanagawa Japan

2. Department of General Pediatric and Hepatobiliary‐Pancreatic Surgery Kitasato University School of Medicine Kanagawa Japan

3. Department of Lower Gastrointestinal Surgery Kitasato University School of Medicine Kanagawa Japan

4. Department of Breast and Thyroid Surgery Kitasato University School of Medicine Kanagawa Japan

5. Division of Advanced Surgical Oncology Department of Research and Development Center for New Medical Frontiers Kitasato University School of Medicine Kanagawa Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14850

Reference28 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

3. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

5. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of CDO1 Gene Promoter Methylation in Tumors;PROG BIOCHEM BIOPHYS;2024

2. Peritoneal Tumor DNA as a Prognostic Biomarker in Gastric Cancer: A Systematic Review and Meta-Analysis;JCO Precision Oncology;2024-03

3. The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review;British Journal of Cancer;2023-09-12

4. Factors Affecting Performance of DNA Methylation as a Potential Biomarker in Ascites for Peritonitis and Peritoneal Carcinomatosis;Journal of Gastrointestinal and Liver Diseases;2023-06-22

5. Cysteine dioxygenase 1 attenuates the proliferation via inducing oxidative stress and integrated stress response in gastric cancer cells;Cell Death Discovery;2022-12-16